PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

INTRODUCTION: In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer. METHODS: Tumor DNA from 140 patients with stage II–III breast cancer undergoing neoadjuvant chemotherapy wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liedtke, Cornelia, Cardone, Luca, Tordai, Attila, Yan, Kai, Gomez, Henry L, Figureoa, Luis J Barajas, Hubbard, Rebekah E, Valero, Vicente, Souchon, Eduardo A, Symmans, W Fraser, Hortobagyi, Gabriel N, Bardelli, Alberto, Pusztai, Lajos
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397526/
https://www.ncbi.nlm.nih.gov/pubmed/18371219
http://dx.doi.org/10.1186/bcr1984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397526/
https://www.ncbi.nlm.nih.gov/pubmed/18371219
http://dx.doi.org/10.1186/bcr1984

Ejemplares similares